Title:
抗ＰＣＳＫ９モノクローナル抗体
Document Type and Number:
Japanese Patent JP6734467
Kind Code:
B2
Abstract:
The application discloses an anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibody, an amino acid sequence comprising coded antibody variable regions and Complementarity-Determining Regions (CDR), the obtaining method , and application of monoclonal antibody. The anti-PCSK9 monoclonal antibodies are screened from a phage antibody library; affinity maturation is achieved by using a method that the phage antibody library is established by means of chain displacement; After screening the light chain CDR1, 2, 3 Mutant Library of monoclonal antibodies obtained from primary screening; monoclonal antibodies having high affinity are selected; then screening the mutant libraries of heavy chain CDR1, 2 , 3 regions ; and finally the monoclonal antibodies having high affinity are screened. The PCSK9 antibody obtained by the application has good affinity to PCSK9 and can inhibit the binding of PCSK9 with its ligand and can be used for treating dyslipidemia, cardiovascular and cerebrovascular diseases and thrombotic occlusion diseases.
Inventors:
White
Lee
Zhang Relax
Sentence Holy Plum
Lee
Zhang Relax
Sentence Holy Plum
Application Number:
JP2019505510A
Publication Date:
August 05, 2020
Filing Date:
December 29, 2017
Export Citation:
Assignee:
BEIJING DONGFANG BIOTECH CO.LTD.
International Classes:
C12N15/13; A61K35/17; A61K39/395; A61K47/55; A61K47/68; A61P3/06; A61P7/02; A61P9/00; A61P43/00; C07K16/40; C12N1/19; C12N1/21; C12N5/10; C12N15/63
Domestic Patent References:
| JP2014511106A |
Foreign References:
| CN105348390A |
Attorney, Agent or Firm:
Yasuhiko Murayama
Shinya Mitsuhiro
Tatsuhiko Abe
Shinya Mitsuhiro
Tatsuhiko Abe